Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2004

View Archived Issues

Isis Pharmaceuticals reports 2003 highlights

Repligen updates product development programs

PSD-95 regulates dopamine-mediated synaptic and behavioral plasticity

Clinical benefits of cholesterol-lowering drugs in patients at high risk of vascular events

Sun Pharma to acquire Hindustan Antibiotics

Orthovisc launched for pain due to osteoarthritis of the knee

Geron and Merix enter coexclusive license agreement for cancer vaccines

Series B funding supports CareX drug development

SBIR grant supports Chimerix drug development for multidrug-resistant HIV

CCR5 antagonists promising candidates against graft rejection

Clinical benefits of iguratimod in rheumatoid arthritis

KRN-1493 ameliorates osteitis fibrosa in rats with secondary hyperparathyroidism

CGS-21680 increases myocardial blood flow in pigs; potential use in myocardial perfusion imaging

New data on OPC-28326, a selective peripheral vasodilator, reported at Japanese Meeting

Effects of TS-011 on cerebral blood flow and infarct size in rats

Enanta claims new bridged erythromycin derivatives with antibacterial activity

Three series of GSK-3 inhibitors patented by GSK

New pegylated HIV fusion inhibitors prepared and tested at Roche

Biomar presents a novel cytotoxic agent isolated from fungal cultures

New quinazoline-based HIV reverse transcriptase inhibitors described by BMS researchers

New alphav integrin inhibitors and their use reported by Sigma-Tau

GenoMed plans West Nile clinical trial

Additional phase II data from Theratope study

FDA Advisory Committee sets date to review RSR-13 NDA

XL-119 receives orphan drug status for bile duct tumors

European approval for Faslodex

DevCo completes lexipafant safety study, seeks commercialization partner

Submission of final section of Onco TCS rolling NDA

NDA seeks approval of fixed-dose coformulation of Viread and Emtriva

Avanir discovers orally active small molecules targeting atherosclerosis

EMEA warns over safety of olanzapine